Fintech PR
EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PanTera, which aims to accelerate global actinium – 225 production
- On track for commercial-scale production of actinium-225, which is crucial to a new class of targeted treatments for cancer
- Largest Series A in life sciences sector in Belgium to date; led by EQT Life Sciences
- Total of EUR 134 million raised including funding secured through EUR 7.2 million equity from IBA and SFPIM, and EUR 33.8 million debt financing
STOCKHOLM, Sept. 11, 2024 /PRNewswire/ — EQT Life Sciences is pleased to announce that it has led a EUR 93 million oversubscribed Series A fundraise in PanTera, the Belgian radioisotope producer. With additional equity and debt funding, the total amount raised is EUR 134 million. The round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV. Alongside this, IBA, the world leader in particle accelerator technology, and SFPIM, a Belgian sovereign fund, will convert into equity EUR 7.2 million convertible loans.
PanTera was founded in 2022 with the primary goal of enabling large-scale production of actinium-225 (225Ac), which is crucial to enable a new class of targeted cancer treatments known as Targeted Alpha Therapy. The funds raised will be used primarily to support the construction of a state-of-the-art production facility in Belgium.
Targeted Alpha Therapy is a promising new cancer treatment approach that enables safe and effective delivery of radiation to the cancer cells by radioisotopes that emit highly energetic alpha particles. The radiation effect of the alpha particle is more localized compared to other approaches and as such can destroy the cancer cells to which it is attached without harming surrounding healthy tissue. The most promising alpha emitter for this approach is 225Ac. As a result, demand for 225Ac is increasing rapidly as drug-development companies look to scale-up clinical trials across a range of different cancers and seek regulatory approvals. However, dependable, scalable and sustainable methods for producing 225Ac are complex and require advanced nuclear infrastructure, which has resulted in a global shortage of the isotope.
PanTera is working to solve this global shortage. The Company’s unique, patented photo-nuclear “gamma” production process transforms Radium-226 (226Ra) into Radium-225 (225Ra), which in turn decays into 225Ac. This process provides a reliable, safe and high-quality supply of 225Ac, not only for clinical trials but also for future commercial radiopharmaceutical therapies, the first of which are due to be on the market in 2028-2029. PanTera’s process and infrastructure is designed to enable the annual production of more than 100 Curies (Ci) of clinical grade 225Ac by 2029, allowing treatment of more than 100,000 patients per year. The combination of SCK CEN’s unmatched large stock of pure 226Ra and IBA’s Rhodotron® electron accelerator, positions PanTera to become a highly successful and reliable producer of this key medical radioisotope.
In parallel to its effort to develop commercial-scale production of 225Ac, PanTera is already providing early 225Ac supply through an alternative production method. Working in collaboration with TerraPower Isotopes, PanTera is on track to provide 1.5-2 Ci of 225Ac annually from early 2025. With today’s current global supply estimated at 3 Ci annually, this will be a significant contribution to drug development. PanTera has signed supply agreements with several pharmaceutical companies, including Bayer, and expects to have secured agreements for more than 80% of its capacity before starting production.
Sven Van den Berghe, CEO of PanTera, said: “PanTera is looking to radically improve supply in the short and long term, in order to ensure that this potentially life-saving, highly innovative modality can reach patients. The size of this raise is testament to our strategy, our unique assets and our capabilities. We are working alongside very experienced partners with a combined expertise and a network that goes well beyond 225Ac production and encompasses all aspects of the radiopharmaceutical revolution. With this funding, we are now en route to realise our vision of providing a “Better Fight for Life” to cancer patients worldwide by becoming a dependable global 225Ac supplier.”
Martijn Kleijwegt, Partner at EQT Life Sciences, commented: “It is clear to us that PanTera has the expertise, assets and strategy in place to address the critical actinium-225 supply shortage faced by the pharmaceutical industry today, as well as the significant increase in demand expected in the future. EQT is one of the world’s largest healthcare investors and we are committed to supporting pioneering ventures, like PanTera, to reach their fullest potential. We are excited to partner with the PanTera team, alongside IBA, SCK CEN and our fellow investors, on the next phase of PanTera’s development.”
Contact
EQT Press Office, [email protected]
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
PR_EQT Life Sciences invests in Pantera_ 11.09.24 |
|
https://news.cision.com/eqt/i/a-lab-microscope-close-up-original-760168,c3332564 |
A Lab Microscope Close-Up original 760168 |
View original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-eur-93-million-oversubscribed-series-a-round-in-pantera-which-aims-to-accelerate-global-actinium—225-production-302244845.html
Fintech PR
Statement From Universal Music Group N.V.
HILVERSUM, Netherlands, Nov. 9, 2024 /PRNewswire/ — “We have taken note of Bill Ackman’s post in relation to Pershing Square and UMG on X yesterday. Neither UMG nor any of its other board members were involved in the formulation of the views in that post. As disclosed in UMG’s listing prospectus, Pershing has the right to request a listing in the US subject to a Pershing entity selling at least $500 million in UMG shares as part of the listing. Pershing does not have any right to require UMG to become a US domiciled company or delist from Euronext Amsterdam. While the company will endeavor in good faith to comply with its contractual obligations with respect to undertaking the process of a US listing at the request of Pershing, any actions or decisions beyond those necessary to comply (including any decisions to change the domicile of the company) will be based on an analysis taking into account what is value maximizing and in the best interests of all the shareholders of the company.”
Logo – https://mma.prnewswire.com/media/512308/5017049/UMG.jpg
View original content:https://www.prnewswire.co.uk/news-releases/statement-from-universal-music-group-nv-302300565.html
Fintech PR
Manulife Investment Management aligns capabilities across regions under the newly created role of Global Emerging Market Equities CIO
LONDON, Nov. 8, 2024 /PRNewswire/ — Manulife Investment Management today announced enhancement to its equity organization in leveraging expertise across its Asia and Emerging Markets teams to improve investment experience for its clients. Charlie Dutton, an equity investment leader with substantial experience in Asia, is named to the newly created role of Chief Investment Officer, Global Emerging Market Equities. In this new role, Charlie will oversee and align our Asia ex-Japan and emerging market equity capabilities, ensuring we leverage local resources and insights across the organization.
Manulife Investment Management has operated in emerging markets for more than a century. Today, it has one of the largest equity teams based in Asia with over 90 investment professionals located across 10 markets in the region. By combining local insight with deep investment expertise, Manulife Investment Management will be able to leverage deeper information advantage over other asset managers based outside of Asia. The combined Emerging Market Equities organization manages over US$25 billion in AUM across Asia and emerging markets equity strategies.
“Collaboration and engagement have always been at the heart of our investment culture, and our emerging markets and Asia equity teams have participated in a variety of forums to exchange ideas and insights. The closer alignment of the Asia equity team with the global Emerging Markets equity organization formalizes the longstanding sharing of ideas and insights between our Asia and our emerging markets equity teams. We believe this alignment will translate into improved research sharing and investment decision making, and will enhance our ability to create custom-tailored solutions to meet client needs,” said Colin Purdie, Global Chief Investment Officer, Public Markets, Manulife Investment Management.
Charlie will be spending a considerable amount of time in Asia with the extensive investment teams across the region in the coming months. He will continue to be based in London, affording him the opportunity to work and communicate with the investment teams in London and across Asia effectively, ensuring connections between each.
Charlie brings more than 27 years of investment experience to this role, including over 25 years of Asia equity investment experience with seven years in Hong Kong as well as South Africa and London. Prior to joining Manulife Investment Management’s Emerging Markets Equity team earlier this year, Charlie was a fund manager at Ninety One as part of the Global Quality Capability team that managed assets across five strategies.
Before Ninety One, Charlie was a founding partner at Coupland Cardiff, an Asian investment firm, where he spent 10 years managing Asian focused equity funds. Prior to that, he was based in Hong Kong and served as director of Asia-Pacific research at JPMorgan and as a Hong Kong/China consumer analyst at JF Securities. Charlie started his career at HSBC based in Hong Kong as a HK/China Analyst.
“We are confident Charlie’s deep investment experience, including over 25 years investing in Asia equity, makes him ideally suited to take on the role of CIO, Emerging Markets Equities. We look forward to his leadership, combined with the support of our Asia investment teams, in building upon our strong foundation in the region, and leading our Asia business into the future,” said Steve Medina, Chief Investment Officer, Global Equities, Manulife Investment Management.
At the same time, Manulife Investment Management announced that Kathryn Langridge, Senior Managing Director, Senior Portfolio Manager, and Head of Emerging Markets Equity team, has shared her intention to retire effective October 31, 2025, after an impressive investment career spanning over 40 years. Meanwhile, Ronald Chan, CIO, Asia ex-Japan Equity, is departing Manulife Investment Management.
“The alignment of the Asia and the Emerging Markets equity teams is a testament to the critical role Asia plays in today’s equity markets, and further draws attention to the deep pool of talent in Manulife’s investment organization,” said Charlie Dutton, Chief Investment Officer, Global Emerging Market Equities. “By globalizing and strengthening this capability, Manulife Investment Management is better positioned to deliver for its clients while expanding the pipeline of research and insight the Emerging Markets equity team can deliver for other capabilities at the firm on a global basis.”
About Manulife Wealth & Asset Management
As part of Manulife Financial Corporation, Manulife Wealth & Asset Management provides global investment, financial advice, and retirement plan services to 19 million individuals, institutions, and retirement plan members worldwide. Our mission is to make decisions easier and lives better by empowering people today to invest for a better tomorrow. As a committed partner to our clients and as a responsible steward of investor capital, we offer a heritage of risk management, deep expertise across public and private markets, and comprehensive retirement plan services. We seek to provide better investment and impact outcomes and to help people confidently save and invest for a more secure financial future. Not all offerings are available in all jurisdictions. For additional information, please visit manulifeim.com.
Media contacts: Carl Wong, Manulife Investment Management Asia, +852 2510 3180, [email protected]; Elizabeth Bartlett, Head of Wealth & Asset Management Public Relations, North America & Europe, Manulife Investment Management, +1 857 210 2286, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/manulife-investment-management-aligns-capabilities-across-regions-under-the-newly-created-role-of-global-emerging-market-equities-cio-302300146.html
Fintech PR
Palm Jebel Ali Project Surges Ahead in 2024: Milestones Achieved in Record Time for Dubai’s Most Anticipated Development
DUBAI, UAE, Nov. 8, 2024 /PRNewswire/ — Nakheel, a member of Dubai Holding’s pioneering real estate arm Dubai Holding Real Estate, has marked significant progress in the development of Palm Jebel Ali in 2024, with the project progressing at pace to meet 2025 milestones.
The development masterplan was approved by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai in May 2023, who said at the time; “Palm Jebel Ali will further strengthen our urban infrastructure and consolidate the city’s emergence as one of the world’s leading metropolises. This new groundbreaking project reflects our strategic development plan centred on raising the quality of life and happiness of residents.”
The Palm Jebel Ali area received further recognition this year when His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence, and Chairman of The Executive Council of Dubai, approved the master plan for the 6.6 kilometre development of Jebel Ali Beach. The project includes a five-kilometre sandy beach, to be developed by Nakheel, as well as a 1.6-kilometre-long Mangrove Beach, to be developed by Dubai Municipality.
Khalid Al Malik, Chief Executive Officer of Dubai Holding Real Estate, said; “At Nakheel we believe in developing dreams, inspired by the vision of our leaders and the hopes of our people. The rapid progress we are currently witnessing on ground at Palm Jebel Ali is testimony to the grand success of our key partnerships and our joint endeavours to ensure we deliver on our commitments.”
Several key contracts for the project were awarded throughout 2024, including the construction of a new 6-kilometre road, the contracts for the island’s marine works, dredging, land reclamation, beach profiling and sand placement, directly supporting the construction of villas. The first eight fronds of the project are expected to be site-ready for villa infrastructure and civil works by the first quarter of 2025.
Crucially, the contract for the construction of exclusive ultra-luxury villas on the first six fronds of the project has also been awarded and are scheduled for completion by late 2026. Nakheel recently announced their partnership with Dubai Electricity and Water Authority for the development of two substations on Palm Jebel Ali.
Video: Palm Jebel Ali
Photo – https://mma.prnewswire.com/media/2552884/Nakheel_1.jpg
Photo – https://mma.prnewswire.com/media/2552885/Nakheel_2.jpg
Photo – https://mma.prnewswire.com/media/2552886/Nakheel_3.jpg
View original content:https://www.prnewswire.co.uk/news-releases/palm-jebel-ali-project-surges-ahead-in-2024-milestones-achieved-in-record-time-for-dubais-most-anticipated-development-302300134.html
-
Fintech5 days ago
Fintech Pulse: Industry Updates on Regulatory Pressures, Fraud Prevention, Humanitarian Finance, and Strategic Sales
-
Fintech3 days ago
Fintech Pulse: The Latest Trends and Insights Shaping Fintech
-
Fintech PR4 days ago
HTX Ventures: Fueling Exchanges’ Transformation into Hubs for DeFi-related Services through Education and Diversification, Empowering investors to Manage Risks and Liquidity in a Volatile Market
-
Fintech PR4 days ago
Smartkem to Present at the 6th National Conference on Organic Field-Effect Transistors in Hangzhou, China
-
Fintech PR2 days ago
Converge Technology Solutions Named Solution Partner of the Year at the 2024 Ingram Micro ONE Innovation Summit
-
Fintech PR2 days ago
Manulife Investment Management aligns capabilities across regions under the newly created role of Global Emerging Market Equities CIO
-
Fintech PR6 days ago
A Tier 1 Insurer in Africa Optimises Data Capabilities with Go-Live of Sapiens Data and Analytics Solution
-
Fintech PR3 days ago
Loyyal’s Xpand Point Partners with Easyrewardz to bring Loyalty Points Exchange for Programs across Middle East, India, Europe and APAC